What does the drug do?

Increased levels of cortisol have been seen in people living with MND. High levels of cortisol can increase inflammation and be toxic to nerve cells, which are associated with MND. Dazucorilant blocks the glucocorticoid receptor, which normally binds to cortisol. Blocking cortisol from binding is thought to limit the consequences of increased cortisol exposure and potentially help slow disease progression. In pre-clinical animal models, Dazucorilant was found to improve motor performance, reduce neuroinflammation and muscular atrophy. 

Phase 2 - DAZALS

Current status: Open to recruitment

DAZALS aims to investigate the safety and efficacy of Dazucorilant in 198 people living with ALS. It is a double blind, placebo control trial where participants will either receive the treatment or placebo (in a 1:1 ratio) for 24-weeks. The trial is also investigating different doses of Dazucorilant, so those who are enrolled in the treatment group will receive either 150 mg or 300 mg (in a 1:1 ratio). Participants who complete the trial will be able to continue into the open-label part of the trial, where all participants will receive the treatment for 24-weeks. Find out more on the MND Clinical Studies Group website or on clinicaltrials.gov.

How can I take part in the trial?

Recruiting Sites

The trial is now recruiting in the UK at the following sites: 

Please contact the individual trial site, by clicking each site above, for more information on how to take part in the trial. 

Trial Information

Phase: Phase 2 

Placebo controlled: Yes - this means that people joining the trial could be randomly assigned to receive the placebo (dummy drug). 

Open-Label Extension: Yes - this means that all participants on the trial, regardless of whether they received the treatment or placebo, will have an opportunity to access the treatment once the randomised part of the trial is complete. 

Latest News


April 2023 - The trial began recruiting in the UK.

Jan 2023 - The trial began recruiting in the Netherlands.

Last updated: 11/03/2024